185 related articles for article (PubMed ID: 26146437)
1. Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.
Millett AJ; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Organometallics; 2015 Jun; 34(11):2683-2694. PubMed ID: 26146437
[TBL] [Abstract][Full Text] [Related]
2. Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C
Liu Z; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
Organometallics; 2014 Oct; 33(19):5324-5333. PubMed ID: 25328266
[TBL] [Abstract][Full Text] [Related]
3. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes.
Liu Z; Salassa L; Habtemariam A; Pizarro AM; Clarkson GJ; Sadler PJ
Inorg Chem; 2011 Jun; 50(12):5777-83. PubMed ID: 21618978
[TBL] [Abstract][Full Text] [Related]
4. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
5. Organometallic half-sandwich iridium anticancer complexes.
Liu Z; Habtemariam A; Pizarro AM; Fletcher SA; Kisova A; Vrana O; Salassa L; Bruijnincx PC; Clarkson GJ; Brabec V; Sadler PJ
J Med Chem; 2011 Apr; 54(8):3011-26. PubMed ID: 21443199
[TBL] [Abstract][Full Text] [Related]
6. Half-sandwich iridium N-heterocyclic carbene anticancer complexes.
Wang C; Liu J; Tian Z; Tian M; Tian L; Zhao W; Liu Z
Dalton Trans; 2017 May; 46(21):6870-6883. PubMed ID: 28405646
[TBL] [Abstract][Full Text] [Related]
7. DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents.
Ritacco I; Russo N; Sicilia E
Inorg Chem; 2015 Nov; 54(22):10801-10. PubMed ID: 26492153
[TBL] [Abstract][Full Text] [Related]
8. Half-Sandwich Iridium(III), Rhodium(III), and Ruthenium(II) Complexes Chelating Hybrid sp
Guo L; Li P; Li J; Gong Y; Li X; Liu Y; Yu K; Liu Z
Inorg Chem; 2023 Sep; 62(37):15118-15137. PubMed ID: 37671819
[TBL] [Abstract][Full Text] [Related]
9. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
11. Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes.
Štarha P; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Inorg Chem; 2016 Mar; 55(5):2324-31. PubMed ID: 26863200
[TBL] [Abstract][Full Text] [Related]
12. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand.
Novohradsky V; Liu Z; Vojtiskova M; Sadler PJ; Brabec V; Kasparkova J
Metallomics; 2014 Mar; 6(3):682-90. PubMed ID: 24448555
[TBL] [Abstract][Full Text] [Related]
14. Triphenylamine-Appended Half-Sandwich Iridium(III) Complexes and Their Biological Applications.
He X; Tian M; Liu X; Tang Y; Shao CF; Gong P; Liu J; Zhang S; Guo L; Liu Z
Chem Asian J; 2018 Jun; 13(11):1500-1509. PubMed ID: 29645357
[TBL] [Abstract][Full Text] [Related]
15. The potent oxidant anticancer activity of organoiridium catalysts.
Liu Z; Romero-Canelón I; Qamar B; Hearn JM; Habtemariam A; Barry NP; Pizarro AM; Clarkson GJ; Sadler PJ
Angew Chem Int Ed Engl; 2014 Apr; 53(15):3941-6. PubMed ID: 24616129
[TBL] [Abstract][Full Text] [Related]
16. Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.
Kong D; Tian M; Guo L; Liu X; Zhang S; Song Y; Meng X; Wu S; Zhang L; Liu Z
J Biol Inorg Chem; 2018 Jul; 23(5):819-832. PubMed ID: 29934699
[TBL] [Abstract][Full Text] [Related]
17. Organoiridium complexes: anticancer agents and catalysts.
Liu Z; Sadler PJ
Acc Chem Res; 2014 Apr; 47(4):1174-85. PubMed ID: 24555658
[TBL] [Abstract][Full Text] [Related]
18. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
19. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
20. Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD(+) and pyruvate, and antiproliferative activity.
Soldevila-Barreda JJ; Habtemariam A; Romero-Canelón I; Sadler PJ
J Inorg Biochem; 2015 Dec; 153():322-333. PubMed ID: 26601938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
